Is White Label Rx multi-month pricing actually cheaper?

Three traps recur. Titration: if a patient on a multi-month semaglutide supply moves up a dose, the remaining lower-dose product may be unusable, so the discount you booked is offset by waste. Drop-off: cash-pay patients churn, and a multi-month supply paid or stocked ahead is a loss if the patient stops. Cash flow: multi-month buys tie up working capital and inventory risk that a monthly cadence does not. Against those, multi-month does offer real upside — fewer orders, less shipping per dose, and simpler refill operations — so the decision is a genuine trade-off, not a clear win.

To evaluate it on White Label Rx, ask for per-vial cost on both month and multi-month options for your top SKUs, then compute per-dose cost under a realistic completion rate rather than 100%. If you expect a meaningful share of patients to titrate or drop off, discount the multi-month savings accordingly. Only compare the adjusted per-dose numbers — that is where the trap shows up or disappears.

Fizy Health shows resolved per-vial 503A cost on each catalog and cart line before checkout, with a separately disclosed facilitation fee at payment. Because cost is visible per vial and per strength, you can model month versus multi-month per-dose economics directly — including the waste a titration change would cause — before you commit, rather than reverse-engineering it from a quoted supply discount.

It also supports a monthly cadence cleanly when that is the safer choice. You can batch a monthly refill day in one cart, see each line's cost, and avoid stocking ahead for patients who may change dose. Compare visible per-dose cost on a monthly cadence against any White Label Rx multi-month quote, adjusted for your real completion rate, to see which actually wins.